. 2010 May;69(5):498–507. doi: 10.1111/j.1365-2125.2010.03616.x

Table 4.

Mean (SD) pharmacokinetic parameters for cimetidine in plasma and urine at steady state after dosing of cimetidine alone and concomitantly with gabapentin enacarbil

		C_ss,max	C_ss,min	t_max	t_1/2	AUC_ss	CL_ss/F	V_d/F	CLr	R
Treatment	n	(µg ml⁻¹)	(µg ml⁻¹)	(h)	(h)	(µg ml⁻¹ h)	(l h⁻¹)	(l)	(l h⁻¹)	(%)
400 mg cimetidine four times daily	12	2.34	0.650	2.42	2.38	8.45	47.9	165	19.9	41.7
		(0.36)	(0.122)	(0.67)	(0.34)	(0.95)	(5.6)	(32)	(4.7)	(9.4)
1200 mg gabapentin enacarbil once daily with 400 mg cimetidine four times daily	12	2.26	0.641	2.42	2.74	8.36	48.5	194	17.1	35.5
		(0.49)	(0.149)	(0.76)	(0.79)	(1.03)	(6.0)	(69)	(4.1)	(9.2)

AUC_ss, area under the concentration–time curve at steady state; CLr, renal clearance; CL_ss/F, apparent clearance after oral dosing at steady state; C_ss,max, maximum concentration at steady state; C_ss,_min, minimum concentration at steady state; R, percentage of cimetidine dose recovered in urine in 6 h post-dose; SD, standard deviation; t_max, time to C_ss,max; t_1/2, half-life; V_d/F, apparent volume of distribution.